Structural Determination, Biological Function, and Molecular Modelling Studies of Sulfoaildenafil Adulterated in Herbal Dietary Supplement
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Tainted Products Marketed As Dietary Supplements
Tainted Products Marketed as Dietary Supplements Jason Humbert, MPS Nicole Kornspan, MPH Regulatory Operations Officer Consumer Safety Officer Food and Drug Administration Office of Regulatory Affairs Health Fraud Branch Overview • Definition of health fraud • Tainted products – then and now • Dietary Supplement Health and Education Act of 1994 (DSHEA) • Concerns related to tainted products • Enforcement challenges • Resources 2 FDA Definition of Health Fraud • The deceptive promotion, advertisement, or sale of products as being effective to diagnose, prevent, cure, treat, or mitigate disease, or to provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes. • May be deliberate, or done without adequate knowledge or understanding of the product. 3 Health Fraud: What are the Risks? • Direct health hazard: product is likely to cause injury, death or other serious adverse effect when used as directed • Indirect health hazard: product poses no direct hazard, but consumer is likely to delay or discontinue appropriate medical treatment by relying on product. 4 4 Tainted Products – Then • 1865-1906: “Golden age” of American quackery • 1905 estimate: 50,000 patent medicines – Drugs were bought and sold like any other consumer good. – Contain dangerous, addictive, misidentified ingredients – Alcohol, cocaine, heroin, opium, without restrictions – Did not have to disclose ingredients – No warnings about misuse – Manufacturer not listed 5 Tainted Products – Now 6 6 Dietary Supplement -
Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry
molecules Article Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry 1,2, 1,3, 4 5 3 Unyong Kim y, Hyun-Deok Cho y, Myung Hee Kang , Joon Hyuk Suh , Han Young Eom , Junghyun Kim 6, Sumin Seo 1, Gunwoo Kim 1, Hye Ryoung Koo 1, Nary Ha 1, Un Tak Song 1 and Sang Beom Han 1,* 1 Department of Pharmaceutical Analysis, College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea; [email protected] (U.K.); [email protected] (H.-D.C.); [email protected] (S.S.); [email protected] (G.K.); [email protected] (H.R.K); [email protected] (N.H.); [email protected] (U.T.S.) 2 Biocomplete Co., Ltd., 272 Digital-ro, Guro-gu, Seoul 08389, Korea 3 Bioanalysis and Pharmacokinetics Study Group, Korea Institute of Toxicology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea; [email protected] 4 Agro-Livestock and Fishery Products Division, Busan Regional Korea Food and Drug Administration, 222 Geoje-daero, Yunje-gu, Busan 47537, Korea; [email protected] 5 Department of Food Science and Human Nutrition, Citrus Research and Education Center, University of Florida, 700 Experiment Station Rd, Lake Alfred, FL 33850, USA; joonhyuksuh@ufl.edu 6 Forensic Toxicology Division, National Forensic Service, 10 Ipchoon-ro, Wonju, Gangwon-do 26460, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-820-5596 These authors contributed equally to this work. y Received: 22 May 2020; Accepted: 9 June 2020; Published: 12 June 2020 Abstract: An accurate and reliable method based on ion trap–time of flight mass spectrometry (IT–TOF MS) was developed for screening phosphodiesterase-5 inhibitors, including sildenafil, vardenafil, and tadalafil, and their analogs in dietary supplements. -
Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate. -
Vardenafil Better Choice for Premature Ejaculation
August 15, 2005 • www.familypracticenews.com Men’s Health 47 Vardenafil Better Choice for Premature Ejaculation BY ROBERT FINN (24%) of the men and was secondary (in On a self-rating scale of 0-8, where 0 Center but is now at the University of San Francisco Bureau most cases to erectile dysfunction) in the means PE almost never, 4 means PE about Hamburg. remaining 26 men (77%). half the time, and 8 means PE almost al- Self-ratings of sexual satisfaction, on a 0- S AN A NTONIO — Vardenafil improved After a 4-week run-in period, 17 men ways, the mean score was 6.14 at baseline, 5 scale, where 0 means not at all satisfied premature ejaculation more than sertra- were given 10-mg vardenafil 10 minutes 4.28 with sertraline, and 3.2 with varde- and 5 means extremely satisfied, averaged line, Frank Sommer, M.D., reported at the before intercourse for 6 weeks. The other nafil. 1.4 at baseline, 3.2 with sertraline, and 4.2 annual meeting of the American Urolog- 17 received 50 mg of sertraline 4 hours be- IVELT, as measured by a stopwatch, with vardenafil. In addition, the partners’ ical Association. fore intercourse. averaged 0.54 minutes at baseline, 2.87 sexual satisfaction showed significant in- Both vardenafil (Levitra), a phosphodi- After a 1-week washout period, the men minutes with sertraline, and 5.23 minutes creases for sertraline and even more so for esterase-5 inhibitor, and sertraline (Zoloft), who had been receiving sertraline with vardenafil, reported Dr. Sommer, vardenafil. -
Wo 2010/075090 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC. -
Repurposing Erectile Dysfunction Drugs Tadalafil and Vardenafil to Increase Bone Mass
Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass Se-Min Kima,b,1, Charit Tanejaa,b, Helena Perez-Penac, Vitaly Ryua,b, Anisa Gumerovaa,b, Wenliang Lic, Naseer Ahmada,b, Ling-Ling Zhua,b, Peng Liua,b, Mehr Mathewa,b, Funda Korkmaza,b, Sakshi Geraa,b, Damini Santa,b, Elina Hadeliaa,b, Kseniia Ievlevaa,b,d, Tan-Chun Kuoa,b, Hirotaka Miyashitaa,b, Li Liue,f, Irina Tourkovae,f, Sarah Stanleyb, Daria Liznevaa,b, Jameel Iqbala,b, Li Suna,b, Ronald Tamlerb, Harry C. Blaire,f, Maria I. Newa,g,1, Shozeb Haiderc, Tony Yuena,b,2, and Mone Zaidia,b,2 aThe Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom; dDepartment of Reproductive Health, Scientific Center for Family Health and Human Reproduction Problems, 664003 Irkutsk, Russian Federation; eDepartment of Pathology, Pittsburgh Veterans Affairs Healthcare System, Pittsburgh, PA 15240; fDepartment of Pathology, University of Pittsburgh, Pittsburgh, PA 15261; and gDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 Contributed by Maria I. New, April 17, 2020 (sent for review January 27, 2020; reviewed by Yousef Abu-Amer, Fayez F. Safadi, and Mei Wan) We report that two widely-used drugs for erectile dysfunction, bone mass, respectively (18, 19). Likewise, soluble guanylate cy- tadalafil and vardenafil, trigger bone gain in mice through a com- clase has also been targeted for bone gain (20, 21). -
Phosphodiesterase (PDE)
Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly. -
Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Diabetes Mellitus
International Journal of Impotence Research (2002) 14, 466–471 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus MA Vickers1,2* and R Satyanarayana1 1Department of Surgery, Togus VA Medical Center, Togus, Maine, USA; and 2Department of Surgery, Division of Urology, University of Massachusetts Medical School, Worcester, Massachusetts, USA Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in ‘general’ and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built. International Journal of Impotence Research (2002) 14, 466–471. doi:10.1038=sj.ijir.3900910 Keywords: phosphodiesterase inhibitor; erectile dysfunction; diabetes mellitus; sildenafil; tadalafil; vardenafil Introduction (NO), vasointestinal peptide and prostacyclin, de- creases. Additionally, the endothelial cells that line the cavernosal arteries and sinusoids have a Pathophysiology of ED in diabetes decreased response to nitric oxide due to increased production of advanced glycation end-products and changes associated with insulin resistance.5,6 The Diabetes mellitus is a risk factor for erectile diabetic also experiences a decreased level of dysfunction (ED). -
1.0 INTRODUCTION the Aim of This Work Is to Validate the Analytical
1.0 INTRODUCTION The aim of this work is to validate the analytical method of quantifying Sildenafil, Vardenafil, Tadalafil and their analogues (Hydroxyhomosildenafil, Norneosildenafil, Acetildenafil, Homosildenafil, Aminotadalafil, Thiosildenafil, N- Desmethylacetildenafil, Thiohomosildenafil, Gendenafil, Carbodenafil, Hydroxythiohomosildenafil, N-Desethylvardenafil, N-Desmethylsildenafil, Udenafil, Hydroxyacetildenafil, Piperiacetildenafil, Dimethylsildenafil, Chloropretadalafil, and Noracetildenafil) using the Liquid Chromatography Tandem Mass Spectrometer (LC- MS/MS) system. This method has been accredited and used daily in the forensic division of the Department of Chemistry (DOC), Malaysia. Sildenafil Citrate (Viagra®), Vardenafil (Levitra®) and Tadalafil (Cialis®) are the only phosphodiesterase-5 (PDE5) enzyme inhibitors approved by the Food and Drugs Administration (FDA) in United State of America to treat male sex problem function or erectile dysfunction if and only if the consumption of those drugs need to be followed and supervised by physicians due to its harmful side-effects. A Phosphodiesterase type 5 inhibitor, often shortened to PDE5 inhibitor, are a drug used to block the degradative action phosphodiesterase-5 enzyme on cyclic GMP in the smooth muscle cells lining the blood vessels supplying one of the part of the penis named corpus cavernosum. Corpus cavernosum is one of a pair of sponge like regions of erectile tissue which contain most of the blood in penis during penile erection (Marshall). Analogue is the term refers to structural derivative of a parent compound that often differs from it by a single element. Or in simple terms can describe as a substance that has major chemical structures in common with another chemical. Unfortunately, no toxicological data of these analogues published and the safety of its largely unknown 1 and unpredictable (James, 2007). -
FOI 043 1516 Document 1
Australian Government Department of Health Therapeutic Goods Administration COUNTERFEIT ERECTILE DYSFUNCTION PRODUCTS The following data has been obtained from the Therapeutic Goods Administration (TGA) Regulatory Compliance Unit and tested by the TGA Laboratories Branch. The products may no longer contain the offending substances, current testing may need to be considered. Version 1 May 2015 IN CONFIDENCE This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health TGA and Australian Customs and Border Security Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means Ylhatsoever, is stricUy prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA. Version 1 May 2015 African Sildenafil, Superman tadalafil and glibenclamide March 2014 Blue Sildenafil Fantasy March 2014 E.O.D Hydroxylhomo Erection On sulfosildenafil, sulfoaildenafil Demand Feb 2014 2 Erec Bull Yohimbine January 2014 Exciting Vardenafil and Dragon acetildenafil Feb 2014 Furunbao Tadalafil January 2014 Hard on Tadalafil Complex Feb 2014 3 Lian Zhan Sildenafil QiTian February 2014 Man Up Sulfoaildenafil Now Feb 2014 Max Hard Sulfosildenafil and aminotadalafil December 2014 4 Maxman Sildenafil Feb 2014 MME Sildenafil Naturally March 2014 Maxman Play Hard Yohimbine and for Men N-desmethyl sildenafil Feb 2014 1om 5 Rock Hard Tadalafil For Men December 2014 Stallion Pro Sulfosildenafil -
Phosphodiesterase Type 5 Inhibitors - a Priority Direction for the Treatment of Erectile Dysfunction of Various Origins
Turkish Journal of Physiotherapy and Rehabilitation; 32(3) ISSN 2651-4451 | e-ISSN 2651-446X PHOSPHODIESTERASE TYPE 5 INHIBITORS - A PRIORITY DIRECTION FOR THE TREATMENT OF ERECTILE DYSFUNCTION OF VARIOUS ORIGINS Gafarov R.R.1, Bobokulov N.A.1, Batirov B.A.1, Muradov S.S.2 1 Samarkand State Medical Institute, 2 Sogda Medical Centre Erectile dysfunction (ED) is a condition in which a man is unable to achieve and maintain an erection to a degree sufficient for successful intercourse. ED is a serious problem affecting both the psychosocial state of the man and his partner [1]. In the ED development, the role of bad habits is great, for example, among smoking men it occurs 20% more often than among nonsmokers [2,3]. ED is associated with various comorbid conditions such as hypertension, hyperlipidemia, metabolic syndrome, lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH), cardiovascular disease, psychological factors, diabetes mellitus, post-radical prostatectomy, antidepressant medication and antihypertensive drugs, etc. (Table 1). Table 1. Pathophysiology of ED [4]. Vasculogenic Recreational habits (i.e., cigarette smoking) Lack of regular physical exercise Obesity Cardiovascular diseases (e.g. hypertension, coronary artery disease, peripheral vasculopathy) Type 1 and 2 diabetes mellitus; hyperlipidaemia; metabolic syndrome; hyperhomocysteinemia Major pelvic surgery (e.g., radical prostatectomy) or radiotherapy (pelvis or retroperitoneum) Neurogenic Central causes Degenerative disorders (e.g., multiple sclerosis, -
Comparative Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction in Diabetic Men: a Bayesian Netw
World Journal of Urology (2019) 37:1061–1074 https://doi.org/10.1007/s00345-018-2583-1 REVIEW Comparative efcacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta‑analysis of randomized controlled trials Xinyang Liao1 · Shi Qiu1 · Yige Bao1 · Wanyu Wang2 · Lu Yang1 · Qiang Wei1 Received: 9 September 2018 / Accepted: 26 November 2018 / Published online: 6 December 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Purpose To compare the efcacy and safety profles of diferent phosphodiesterase-5 inhibitors (PDE5Is) administrations for erectile dysfunction (ED) in diabetic men, including on-demand (PRN) and regular regimens (OAD). Materials and methods Searches were carried out in four electronic databases: PubMed (until April 17th, 2017); Scopus (until April 17th, 2017); Embase (until April 17th, 2017); and Cochrane (until April 18th, 2017). The outcomes for this study are as follows: (1) Global Assessment Question (GAQ) positive response rate; (2) changes from baseline to the end of the study in Erectile Function Domain of International Index of Erectile Function (IIEF-EF); and (3) treatment-related adverse events (TRAEs). The comparative efects of PDE5I regimens were analyzed with random-efect models in a Bayes- ian Framework using the GeMTC R package. Results We identifed 1056 records, of which 15 randomized trials with 5274 patients were included. The included stud- ies covered eight kinds of PDE5I administration: avanafl PRN; mirodenafl PRN; sildenafl PRN; tadalafl PRN; tadalafl OAD; udenafl PRN; udenafl OAD; vardenafl PRN; and placebo. In surface under the cumulative ranking curve analysis, vardenafl PRN ranked frst, third and frst, and mirodenafl PRN ranked second, frst and second in GAQ, IIEF-EF, and TRAEs, respectively.